Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

DreamHug Medical vs NuuVim

DreamHug Medical
Graded #386

Lower grade

vs+10.300000000000004
NuuVim
Graded #153

Higher grade

The verdict

NuuVim takes it — 68.2/100 to 57.9/100.

NuuVim grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. NuuVim is a Texas-based DTC telehealth program offering compounded semaglutide and tirzepatide in both injectable and oral forms — oral access is uncommon here — plus limited brand-name Ozempic and Zepbound.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueNuuVim +31
57
88
Dose & formulationNuuVim +32
64
96
Clinical oversightDreamHug Medical +18
60
42
Labs & monitoringEven
50
50
FulfillmentDreamHug Medical +6
67
61
Contract termsNuuVim +6
41
47
DreamHug Medical · left barNuuVim · right bar

The numbers

MetricDreamHug MedicalNuuVim
WeighScore57.9/10068.2/100
GradeCC
Scorecard rank#386#153
Semaglutide$188/mo (starting dose, compounded)$79/mo (all doses, 3-mo plan, new patients only, compounded)
Tirzepatide$238/mo (starting dose, compounded)$133/mo (all doses, 3-mo plan, new patients only, compounded)
CoverageAll 50 statesCoverage not published
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyYes
DreamHug Medical

Graded #386 · C

Strengths

  • Florida business address disclosed publicly (Pompano Beach, FL) — more transparency than many DTC competitors
  • 100% money-back guarantee if you're not approved
  • Telehealth-only with claimed all-50-state coverage via an 11,000-doctor network
  • LegitScript logo displayed

Where it loses points

  • Tirzepatide not mentioned — semaglutide-only, narrower scope than competitors
  • Pricing not disclosed — fully gated behind sign-up
  • LegitScript ID number not shown (only the logo)
  • Pharmacy partner not disclosed
  • Named medical director not disclosed
NuuVim

Graded #153 · C

Strengths

  • Low compounded entry pricing — semaglutide from $79/mo, tirzepatide from $133/mo, flat all-dose pricing
  • Both injectable and oral compounded options for semaglutide and tirzepatide (oral access is uncommon)
  • LegitScript Certified and HIPAA-compliant
  • Two named compounding pharmacy partners (Hallandale Pharmacy and Pharmacy Hub), both vetted in our directory
  • Operating legal entity disclosed: NuuVim LLC, Texas governing law

Where it loses points

  • There is no month-to-month plan: every rate is billed as one three-month payment
  • The advertised $79 and $133 are introductory rates for customers new to GLP-1s; on renewal they become $133 and $199.67
  • The site's own llms.txt advertises pricing, FAQ and terms files that all 404
  • No state count is published
  • FDA issued this company a warning letter dated 19 March 2025; the letter is public in FDA's warning-letter database

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard